Welcome and Opening Remarks
Beth DelGiacco, Vice President, Corporate Communications & Investor Relations, argenx
argenx Vision 2030
Tim Van Hauwermeiren, Chief Executive Officer and Co-Founder, argenx
Our Blueprint for Immunology Innovation
Collaborative Approach to Discovery
Peter Ulrichts, Ph.D., Chief Scientific Officer, argenx
Applying Learnings in FcRn to New Molecules
Karen Silence, Ph.D., Head Preclinical Product Development, argenx
Clinical Development
Luc Truyen, Ph.D., M.D., Chief Medical Officer, argenx
Leadership in FcRn
Sjogren’s Disease
Julie Jacobs, Ph.D., Principal Scientist, argenx
Myositis
Leentje De Ceuninck, Ph.D., Senior Clinical Scientist, argenx
Sjogren’s Panel: Exploring Unmet Need & Clinical Insights
Moderated by Luc Truyen, Ph.D., M.D., Chief Medical Officer, argenx
Simon Bowman, Ph.D., M.B.B.S., F.R.C.P., Honorary Professor of Rheumatology, University of Birmingham
Julie Jacobs, Ph.D. Principal Scientist, argenx
Pioneering C2 Development
Jeffrey Guptill, M.D., Neuromuscular Franchise Lead, Clinical Development, argenx
Inge Van de Walle, Ph.D., Research Fellow, argenx
Neurology Panel: Expanding Patient Reach with Empasiprubart in MMN
Moderated by Jeffrey Guptill, M.D., Neuromuscular Franchise Lead, Clinical Development, argenx
Patrick Kwon, M.D., Clinical Associate Professor of Neurology, New York University
Luc Truyen, Ph.D., M.D., Chief Medical Officer, argenx
Sustainable Commercial Engine
Karen Massey, Chief Operating Officer, argenx